NDAINTRA-ARTERIALSOLUTION
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
18/100
Data completeness
3/8 — Basic
IOMERVU (iomeprol injection) by Bracco is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2024.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IOMERVU (iomeprol injection) is an intra-arterial radiographic contrast agent approved November 2024 for diagnostic imaging procedures. It works via X-ray contrast activity to enhance visualization of vascular and organ structures during angiographic and interventional procedures. The agent improves image quality during arterial catheterization and related diagnostic imaging.
Growth3.6 years to LOE
Early-stage growth product with established sponsor infrastructure; commercial teams are likely building launch momentum with focused field and medical affairs expansion.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Why This Matters for Your Career
Worked on IOMERVU at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.